Year-end Round-Up – Your favourite PharmaMedic articles of 2020 4 Jan 2021

As we reflect back to one of the most unusual years in memory we can recall, we would like to take the opportunity to thank all our clients, consultants, and readers for following PharmaMedic content and articles last year.  We have written on a range of topics from the skills we need to cultivate in the era of COVID-19, to the future we might expect for the MHRA in a post-Brexit Britain.

In this short round-up we recap the top three PharmaMedic articles that were the most widely read and resonated most with our readers and audience last year.

1) Q&A with Lucy Cook – A PharmaMedic Consultant

In this article we interviewed Dr Lucy Cook, a valued member of the PharmaMedic team to learn about her experience in medical affairs and discuss how we help her to do more of the technical work she enjoys without the traditional headaches of self-employment.

2) Deeper Dive into PharmaMedic’s VirtualPharma™ Solution

In this article we gave some insights into the structure of our flexible and cost-effective medical affairs solution and outlined the four key pillars of our approach.  We support a diverse portfolio of customers by providing full medical and regulatory input throughout the product lifecycle.

3) Interview with Olivia Marsh at Glenmark Pharmaceuticals

At PharmaMedic we work closely with marketing colleagues and in this case study interview we talk with one of our longstanding clients, Olivia Marsh about how we support her and the Glenmark Pharmaceuticals team with the development of promotional materials and marketing for several respiratory branded generics.  As well as the day-to-day practical input offered, Olivia particularly appreciates the additional perspectives our consultant brings to the table on broader industry trends.

While 2020 took an unexpected turn, we can draw some positives.  For one, the ingenuity of the global life sciences industry has come to the fore with accelerated development timelines and strong industry and regulatory collaboration.  We can look ahead with cautious optimism to the next 12 months knowing that new medicines and vaccines stand a good chance of turning the tide of the pandemic.  As pharmaceutical professionals and consultants we remain steadfast in our commitment to helping organisations of all sizes navigate this complex and ever-changing medical and regulatory landscape.

We would love to hear from you about the hot topics you would like us to cover in the coming months.  Do get in touch if you would be interested in being interviewed for our news section or would like to guest author a thought leadership piece.